Image-guided Radiotherapy for Prostate Cancer
(MIDAS-Prostate Trial)
Trial Summary
What is the purpose of this trial?
This is a Phase II prospective sing-arm trial that is recruiting 60 participants from patients that have biochemical failure after radical prostatectomy with local or regional recurrence proven by PSMA PET. Participants of this study will receive molecular imaging informed radiation dose escalation to site of recurrent disease and de-escalation to uninvolved areas. Participants will be follow-up as per standard of care up to 5 years post-treatment.
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Image-guided Radiotherapy for Prostate Cancer?
Research shows that Image-guided Radiotherapy (IGRT) improves the accuracy of radiation delivery, which can reduce side effects and improve outcomes for prostate cancer patients. Studies have found that IGRT, especially when combined with intensity-modulated radiation therapy (IMRT), results in lower toxicity and better control of cancer compared to older methods without daily image guidance.12345
Is image-guided radiotherapy (IGRT) safe for humans?
How is Image-guided Radiotherapy (IGRT) different from other treatments for prostate cancer?
Image-guided Radiotherapy (IGRT) is unique because it uses imaging techniques like ultrasound and cone beam CT to precisely target the prostate, allowing for more accurate radiation delivery and reducing damage to surrounding healthy tissue. This precision helps in adapting to daily changes in prostate position, which can improve treatment outcomes and reduce side effects compared to traditional radiotherapy methods.12348
Eligibility Criteria
This trial is for men over 18 with a history of prostate cancer, who've had surgery but are now experiencing a relapse confirmed by PSMA PET scans. They should be relatively healthy and active (ECOG 0-1) and have no more than five positive nodes on their scan. Men with contraindications to radiation, distant metastasis, chronic pelvic inflammation, or previous pelvic radiation can't join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive molecular imaging informed radiation dose escalation to sites of recurrent disease and de-escalation to uninvolved areas
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Image-guided Radiotherapy
Image-guided Radiotherapy is already approved in United States, European Union, Canada, Japan for the following indications:
- Prostate cancer
- Various cancers requiring radiation therapy
- Prostate cancer
- Various cancers requiring radiation therapy
- Prostate cancer
- Various cancers requiring radiation therapy
- Prostate cancer
- Various cancers requiring radiation therapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Health Network, Toronto
Lead Sponsor